Preclinical research forms the critical bridge between radiopharmaceutical discovery and first-in-human clinical trials, encompassing in vitro characterization, in vivo biodistribution, dosimetry, and toxicology studies that collectively define a compound's safety profile and therapeutic potential. Protheragen delivers integrated radiopharmaceutical preclinical research services—from cell-based binding assays and micro-PET/SPECT imaging to GLP-compliant IND-enabling toxicology—designed to accelerate your program from lead compound to clinical translation with scientific rigor and regulatory foresight.
Radiopharmaceutical preclinical research encompasses a systematic, multi-tiered evaluation of candidate compounds before they enter human clinical trials. Unlike conventional pharmaceuticals, radiopharmaceuticals present unique preclinical challenges because their efficacy and toxicity are governed by the interplay between radiation dose delivered to target and non-target tissues, the biological half-life of the radiolabeled compound, and the radiosensitivity of the exposed organs. Preclinical studies must therefore characterize not only the pharmacological properties of the targeting ligand but also the radiochemical purity, specific activity, and dosimetric profile of the final formulation.
Fig 1. Overview of theranostic imaging and therapeutic radionuclide categories. (Nelson, Bryce JB, et al., 2024)
Protheragen provides comprehensive radiopharmaceutical preclinical research services that span the full development continuum—from in vitro binding and internalization assays through in vivo micro-PET/SPECT imaging, biodistribution, dosimetry, and GLP-compliant IND-enabling toxicology. Our integrated platform combines dedicated radiochemistry facilities, shielded animal imaging suites, and multidisciplinary expertise in nuclear medicine, pharmacology, and regulatory science to deliver robust, reproducible preclinical data packages. Whether your program requires a rapid screening package for lead optimization or a full IND-enabling toxicology and dosimetry campaign, Protheragen offers the specialized infrastructure and scientific depth to accelerate your radiopharmaceutical from bench to bedside.
We provide layered in vitro & in vivo efficacy testing platforms to quantify tumor-targeting capacity and anti-tumor potency of radiopharmaceuticals.
Protein level: Radioligand target affinity binding assay
Cell level
-Radiopharmaceutical cellular uptake & receptor internalization test
-Target binding affinity and specificity characterization
-Tumor cell killing efficacy assessment of radiolabeled agents
-Xenograft tumor-bearing animal model efficacy studies for therapeutic radiopharmaceuticals (peptides, small molecules, antibody radioconjugates labeled with ¹⁷⁷Lu, ²²⁵Ac etc.)
-Longitudinal tumor growth inhibition monitoring to quantify anti-tumor therapeutic effects
Integrated in vitro metabolic screening and cross-species in vivo PK/PD & imaging platform to characterize absorption, distribution, metabolism, excretion and internal radiation dosimetry of radiotracers.
-Protein binding / heat drug affinity assay
-Radiopharmaceutical metabolic stability profiling
-Cross-species PK studies (mice, rats, beagle dogs, miniature pigs, non-human primates)
-Whole tissue biodistribution analysis & internal radiation dosimetry calculation
-Radiopharmaceutical excretion pathway assessment in rodents
-Tumor-bearing mouse biodistribution test
-Quantitative micro-PET / micro-SPECT / CT in vivo imaging for radiotracer visualization
Complete GLP-standardized safety toxicology screening system covering acute, repeated-dose and local irritation/allergic tests across multiple laboratory animal species.
Our preclinical research workflow follows a structured, evidence-based progression that integrates in vitro screening, in vivo pharmacokinetic evaluation, and regulatory-compliant toxicology to generate a comprehensive data package for IND submission. Each phase builds upon the preceding one, ensuring that only compounds with demonstrated target specificity, favorable biodistribution, and acceptable safety margins advance to clinical translation.
Ready to advance your radiopharmaceutical program with rigorous, regulatory-compliant preclinical research? Contact us today to discuss how Protheragen can support your development pipeline—from in vitro lead optimization and in vivo biodistribution through GLP toxicology and IND-enabling studies. Our team is prepared to reach out to you with a customized study proposal tailored to your specific compound, target, and regulatory pathway. Let us help you build the robust preclinical evidence foundation needed to bring your next-generation radiopharmaceutical from concept to clinic.
Reference